A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

Gómez-Zorrilla, Silvia ; Becerra-Aparicio, Federico ; López Montesinos, Inmaculada ; Ruiz de Gopegui, Enrique ; Grau, Inmaculada ; Pintado, Vicente ; Padilla, Belén ; Benito, Natividad ; Boix-Palop, Lucía ; Fariñas, Maria Carmen ; Peñaranda, María ; Gamallo, Maria Rocío ; Martinez, Jose Antonio ; Morte-Romea, Elena (Universidad de Zaragoza) ; Del Pozo, Jose Luis ; Durán-Jordá, Xavier ; Díaz-Regañón, Jazmin ; López-Mendoza, Diego ; Cantón, Rafael ; Oliver, Antonio ; Ruiz-Garbajosa, Patricia ; Horcajada, Juan Pablo ; Siverio, Ana ; Gijón, Desiré ; Merino, Irene ; López-Causapé, Carla ; Sabé, Nuria ; Shaw, Evelyn ; Berbel, Dámaris ; Tubau Quintano, Fe ; Sánchez Carrillo, Carlos ; Cercenado, Emilia ; Sendra, Elena ; Rubio, Verónica ; Rivera, Alba ; Calvo, Esther ; Badía, Cristina ; Xercavins, Mariona ; de Malet, Ana ; Canoura-Fernández, Luis ; Salvo, Soledad ; Paño-Pardo, Jose Ramón (Universidad de Zaragoza) ; Carmona-Torre, Francisco

Resumen: Introduction: Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. Methods: ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract. The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Results: Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77–6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27–6.44) and Charlson index (aOR 1.11; 95% CI 1.01–1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40–0.93) were less likely to present clinical cure. Conclusion: The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. © 2021, The Author(s).

Idioma: Inglés

DOI: 10.1007/s40121-021-00537-0

Año: 2021

Publicado en: Infectious Diseases and Therapy 10, 4 (2021), 2677-2699
ISSN: 2193-8229

Factor impacto JCR: 6.119 (2021)

Categ. JCR: INFECTIOUS DISEASES rank: 26 / 96 = 0.271 (2021) - Q2 - T1

Factor impacto CITESCORE: 6.1 - Medicine (Q1)

Factor impacto SCIMAGO: 1.141 - Microbiology (medical) (Q1) - Infectious Diseases (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0004
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0005
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0007
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0010
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0011
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0015

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)